Last reviewed · How we verify
Lergitin (phenbenzamine)
Lergitin (generic name: phenbenzamine) is a phenbenzamine drug. It is currently in unknown development.
Lergitin works by blocking certain receptors in the body, although the specific receptors and pathways involved are not well understood.
Lergitin (phenbenzamine) is a small molecule drug of the phenbenzamine class. Its mechanism of action is not well established, and it is not FDA approved for any indications. As a result, there is limited information available on its commercial status, safety considerations, or pharmacokinetic properties. Further research is needed to fully understand the properties and potential uses of Lergitin. Due to its lack of FDA approval, it is not currently available as a prescription medication.
At a glance
| Generic name | phenbenzamine |
|---|---|
| Drug class | phenbenzamine |
| Therapeutic area | Neuroscience |
| Phase | unknown |
Mechanism of action
Think of it like a key fitting into a lock. Lergitin is like a key that blocks the action of certain chemicals in the body, but we don't yet know which lock it fits into or what the consequences of blocking those chemicals might be.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lergitin CI brief — competitive landscape report
- Lergitin updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Lergitin
What is Lergitin?
How does Lergitin work?
What is the generic name of Lergitin?
What drug class is Lergitin in?
What development phase is Lergitin in?
Related
- Drug class: All phenbenzamine drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing